United States - English - NLM (National Library of Medicine)

janssen products, lp - doxorubicin hydrochloride (unii: 82f2g7bl4e) (doxorubicin - unii:80168379ag) - doxorubicin hydrochloride 2 mg in 1 ml - doxorubicin hydrochloride liposome injection is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy. doxorubicin hydrochloride liposome injection is indicated for the treatment of aids-related kaposi's sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy. doxorubicin hydrochloride liposome injection, in combination with bortezomib, is indicated for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy. doxorubicin hydrochloride liposome injection is contraindicated in patients who have a history of severe hypersensitivity reactions, including anaphylaxis, to doxorubicin hydrochloride [see warnings and precautions (5.2)]. risk summary based on findings in animals and its mechanism of action, doxorubicin hydrochloride liposome injection can cause fetal harm when administered to a pregnant woman; avoid the

United States - English - NLM (National Library of Medicine)

northstar rxllc - doxorubicin hydrochloride (unii: 82f2g7bl4e) (doxorubicin - unii:80168379ag) - doxorubicin hydrochloride 2 mg in 1 ml - doxorubicin hydrochloride liposome injection is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy. doxorubicin hydrochloride liposome injection is indicated for the treatment of aids-related kaposi’s sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy. doxorubicin hydrochloride liposome injection, in combination with bortezomib, is indicated for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy. doxorubicin hydrochloride liposome injection is contraindicated in patients who have a history of severe hypersensitivity reactions, including anaphylaxis, to doxorubicin hydrochloride [see warnings and precautions (5.2)]. risk summary based on findings in animals and its mechanism of action, doxorubicin hydrochloride liposome injection can cause fetal harm when administered to a pregnant woman; avoid the

United States - English - NLM (National Library of Medicine)

dr. reddy's laboratories inc - doxorubicin hydrochloride (unii: 82f2g7bl4e) (doxorubicin - unii:80168379ag) - doxorubicin hydrochloride 2 mg in 1 ml - doxorubicin hydrochloride liposome injection is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy. doxorubicin hydrochloride liposome injection is indicated for the treatment of aids-related kaposi’s sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy. doxorubicin hydrochloride liposome injection, in combination with bortezomib, is indicated for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy. doxorubicin hydrochloride liposome injection is contraindicated in patients who have a history of severe hypersensitivity reactions, including anaphylaxis, to doxorubicin hydrochloride [see warnings and precautions (5.2)]. risk summary based on findings in animals and its mechanism of action, doxorubicin hydrochloride liposome injection can cause fetal harm when administered to a pregnant woman; avoid the

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - doxorubicin hydrochloride (unii: 82f2g7bl4e) (doxorubicin - unii:80168379ag) - doxorubicin hydrochloride 2 mg in 1 ml - doxorubicin hydrochloride liposome injection is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy. doxorubicin hydrochloride liposome injection is indicated for the treatment of aids-related kaposi's sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy. doxorubicin hydrochloride liposome injection, in combination with bortezomib, is indicated for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy. doxorubicin hydrochloride liposome injection is contraindicated in patients who have a history of severe hypersensitivity reactions, including anaphylaxis, to doxorubicin hydrochloride [see warnings and precautions (5.2)]. risk summary based on findings in animals and its mechanism of action, doxorubicin hydrochloride liposome injection can cause fetal harm when administered to a pregnant woman; avoid the

United States - English - NLM (National Library of Medicine)

bluepoint laboratories - doxorubicin hydrochloride (unii: 82f2g7bl4e) (doxorubicin - unii:80168379ag) - doxorubicin hydrochloride 2 mg in 1 ml - doxorubicin hydrochloride liposome injection is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy. doxorubicin hydrochloride liposome injection is indicated for the treatment of aids-related kaposi’s sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy. doxorubicin hydrochloride liposome injection, in combination with bortezomib, is indicated for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy. doxorubicin hydrochloride liposome injection is contraindicated in patients who have a history of severe hypersensitivity reactions, including anaphylaxis, to doxorubicin hydrochloride [see warnings and precautions ( 5.2)]. risk summary based on findings in animals and its mechanisms of action, doxorubicin hydrochloride liposome injection can cause fetal harm when administered t

United States - English - NLM (National Library of Medicine)

dr. reddy's laboratories inc - doxorubicin hydrochloride (unii: 82f2g7bl4e) (doxorubicin - unii:80168379ag) - doxorubicin hydrochloride 2 mg in 1 ml - doxorubicin hydrochloride liposome injection is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy. doxorubicin hydrochloride liposome injection is indicated for the treatment of aids-related kaposi’s sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy. doxorubicin hydrochloride liposome injection, in combination with bortezomib, is indicated for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy. doxorubicin hydrochloride liposome injection is contraindicated in patients who have a history of severe hypersensitivity reactions, including anaphylaxis, to doxorubicin hydrochloride [see warnings and precautions (5.2)]. risk summary based on findings in animals and its mechanism of action, doxorubicin hydrochloride liposome injection can cause fetal harm when administered to a pregnant woman; avoid the

Canada - English - Health Canada

teva canada limited - doxorubicin hydrochloride - solution - 2mg - doxorubicin hydrochloride 2mg - antineoplastic agents

Canada - English - Health Canada

sandoz canada incorporated - doxorubicin hydrochloride - solution - 2mg - doxorubicin hydrochloride 2mg - antineoplastic agents

Canada - English - Health Canada

pfizer canada ulc - doxorubicin hydrochloride - solution - 2mg - doxorubicin hydrochloride 2mg - antineoplastic agents

Ireland - English - HPRA (Health Products Regulatory Authority)

cell pharm gmbh - doxorubicin hydrochloride - solution for injection - 2 milligram(s)/millilitre - anthracyclines and related substances; doxorubicin